The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats
Abstract
Silymarin (SIL), a standardized plant extract containing about 60% polyphenole silibinin, is used as a hepatoprotective agent. Its antifibrotic potential in chronic liver diseases has not been explored. Therefore, we applied SIL to adult Wistar rats that were subjected to complete bile duct occlusion (BDO) by injection of sodium amidotrizoate (Ethibloc). This treatment induces progressive portal fibrosis without significant inflammation. Rats with sham-operation that received SIL at 50 mg/kg/d (n = 10) and rats with BDO alone (n = 20) served as controls, whereas groups of 20 animals were fed SIL at a dose of 25 and 50 mg/kg/d during weeks 1 through 6 or doses of 50 mg/kg/d during weeks 4 through 6 of BDO. Animals were sacrificed after 6 weeks for determination of blood chemistries, total and relative liver collagen (as hydroxyproline [HYP]), and the serum aminoterminal propeptide of procollagen type III (PIIINP). BDO in untreated rats caused an almost ninefold increase in total liver collagen (16.1 ± 3.1 vs. 1.8 ± 0.4 mg HYP, P < .001). SIL at 50 mg/kg/d reduced total HYP by 30% to 35%, either when given from week 1 through 6 or from week 4 through 6 after BDO (10.6 ± 2.7 and 10.2 ± 3.9 mg HYP, both P < .01 vs. BDO alone), whereas 25 mg/kg/d were ineffective. Because SIL at 50 mg/kg/d also reduced the collagen content per gram of liver tissue, it acted as a true antifibrotic agent. The single value of PIIINP at killing paralleled the antifibrotic activity of SIL with 11.6 ± 3.8 and 9.9 ± 3.7 vs. 15.3 ± 5.2 microg/L in both high-dose groups (P < .05 and P < .01, respectively, vs. rats with BDO alone). Except for a decreased alkaline phosphatase and a lower histological fibrosis score in the groups that received SIL, clinical-chemical parameters were not different among all groups with BDO. We therefore conclude that 1) BDO with Ethibloc is a suitable model to test for pure antifibrotic drugs because it induces progressive rat secondary biliary fibrosis without major inflammation; 2) oral SIL can ameliorate hepatic collagen accumulation even in advanced (biliary) fibrosis; and 3) PIIINP appears to be a suitable serum marker to monitor the inhibition of hepatic fibrogenesis in this model of biliary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knodell, R. G., Ishak, K. G., Black, W. C., Chen, T. S., Craig, R., Kaplowitz, N., Kiernan, T. W., & Wollman, J. (1981) · Hepatology · doi:10.1002/hep.1840010511 · Cited by 3,522
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues
Jamall, I. S., Finelli, V. N., & Que Hee, S. S. (1981) · Analytical Biochemistry · doi:10.1016/0003-2697(81)90261-x · Cited by 518
Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver
Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W., & Schneider, B. (1989) · Journal of Hepatology · doi:10.1016/0168-8278(89)90083-4 · Cited by 496
Silymarin protects against paracetamol‐induced lipid peroxidation and liver damage
Muriel, P., Garciapiña, T., Perez‐Alvarez, V., & Mourelle, M. (1992) · Journal of Applied Toxicology · doi:10.1002/jat.2550120613 · Cited by 301
Dehmlow, C., Erhard, J., & de Groot, H. (1996) · Hepatology · doi:10.1002/hep.510230415 · Cited by 290
Scavenging of reactive oxygen species by silibinin dihemisuccinate
Mira, L., Silva, M., & Manso, C. F. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90053-1 · Cited by 192
PREVENTION OF CCL4‐INDUCED LIVER CIRRHOSIS BY SILYMARIN
MOURELLE, M., MURIEL, P., FAVARI, L., & FRANCO, T. (1989) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.1989.tb00449.x · Cited by 159
BOSISIO, E. (1992) · Pharmacological Research · doi:10.1016/1043-6618(92)91383-r · Cited by 158
Suppression of experimental hepatic fibrosis by administration of vitamin A.
Senoo, H., & Wake, K. (1985) · PubMed · Cited by 158
LIU, S., Esposti, S. D., Yao, T., Diehl, A. M., & Zern, M. A. (1995) · Hepatology · doi:10.1002/hep.1840220522 · Cited by 155
Valenzuela, A., Lagos, C., Schmidt, K., & Videla, L. A. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90421-6 · Cited by 142
Parola, M., Muraca, R., Dianzani, I., Barrera, G., Leonarduzzi, G., Bendinelli, P., Piccoletti, R., & Poli, G. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81290-3 · Cited by 135
Role of free radicals in liver diseases and hepatic fibrosis.
Britton, R. S., & Bacon, B. R. (1994) · PubMed · Cited by 129
Vitamin A deficiency potentiates carbon tetrachloride-induced liver fibrosis in rats
Seifert, W. F., Bosma, A., Brouwer, A., Hendriks, H., Roholl, P. J. M., van Leeuwen, R. E. W., Ruiter, C. F. V. T.-D., Seifert-Bock, I., & Knook, D. L. (1994) · Hepatology · doi:10.1002/hep.1840190129 · Cited by 97
Agarwal, R., Katiyar, S. K., Lundgren, D. W., & Mukhtar, H. (1994) · Carcinogenesis · doi:10.1093/carcin/15.6.1099 · Cited by 97
Sonnenbichler, J., Goldbero, M., Hane, L., Madubunyi, I. I., Vogl, S., & Isolde, Z. E. T. L. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90233-9 · Cited by 85
Caffeine demethylation measured by breath analysis in experimental liver injury in the rat
Schaad, H. J., Renner, E. L., Wietholtz, H., Arnaud, M. J., & Preisig, R. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80264-9 · Cited by 82
Schuppan, D., Dumont, J., Kim, K. Y., et al. (1986) · Journal of Hepatology · doi:10.1016/s0168-8278(86)80142-8 · Cited by 65
Self-citationGressner, A. M. (1992) · PubMed · Cited by 63
McCay, P. B., Brueggemann, G., Lai, E. K., & Powell, S. R. (1989) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1989.tb14906.x · Cited by 53
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
“The consideration as a hepatoprotective agent is due to experimental data indicating potential prevention of hepatic injury by toxins and deceleration of fibrosis progression by the main ingredient, silibinin [359,360].”
BackgroundOxidative stress-related molecules and liver fibrosis
Parola, M., & Robino, G. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00142-8 · Cited by 783
The Use of Silymarin in the Treatment of Liver Diseases
Saller, R., Meier, R., & Brignoli, R. (2001) · Drugs · doi:10.2165/00003495-200161140-00003 · Cited by 718
Milk thistle in liver diseases: past, present, future
Abenavoli, L., Capasso, R., Milic, N., & Capasso, F. (2010) · Phytotherapy Research · doi:10.1002/ptr.3207 · Cited by 599
Cutaneous photodamage, oxidative stress, and topical antioxidant protection
Pinnell, S. R. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.16 · Cited by 544
Metadata
- Authors
- Boigk, G., Stroedter, L., Herbst, H., Waldschmidt, J., Riecken, E. O., & Schuppan, D.
- Venue
- Hepatology
- Published
- 1997-09
- Volume
- 26
- Issue
- 3
- Pages
- 643-649
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1965452357
- Cited by
- 293
- References
- 21
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.